69.2701.26% ( +0.860 )
Trading: Oct 22, 10:44:31 (EDT)Current ValuationThe current P/E ratio is -254.96, within the reasonable range, cheaper than 73.52% of the time in the past 5 years, and the industry ranks 61/74, the industry Median --.
-254.96xP/E
$68.41Stock price
$-0.27Earnings per share
-254.96xP/E
Stock price$68.41Earnings per share$-0.27
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 47.82x
- Typical range
- -308.30x–467.19x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -49.32x | 2.97% | $22.37B |
HIMSUSHims & Hers Health | -47.98x | 209.86% | $6.82B |
RDNTUSRadnet | -254.96x | 128.00% | $5.38B |
NEOUSNeogenomics | -42.20x | 64.12% | $2.19B |
WGSUSGeneDx | -19.33x | 359.59% | $2.06B |
AGLUSagilon health | -6.58x | 92.48% | $1.53B |
INNVUSInnovage | -491.59x | 2,301.70% | $1.25B |
OPKUSOpko Health | -16.38x | 25.99% | $1.19B |
CSTLUSCastle Biosciences | -54.08x | 51.54% | $1.05B |
LMRIUSLumexa Imaging | -37.45x | 145.51% | $1.04B |
AONCUSAmerican Oncology Network | -- | -- | $711.62M |
GMRSUSGMR Solutions | -7.43x | 91.45% | $561.83M |
FLGTUSFulgent Genetics | -6.56x | 42.64% | $553.88M |
PREUSPrenetics Global | -6.10x | 15.02% | $286.81M |
BDSXUSBiodesix | -9.09x | 42.77% | $252.49M |
GAMGUSGlobal Asset Management Group, Inc. | -351.59x | -- | $198.45M |
NAKAUSNakamoto | -0.36x | 102.50% | $151.12M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
PARKUSPark Dental Partners | -26.80x | -- | $94.73M |
AIRSUSAirSculpt Tech | -7.86x | 33.33% | $92.28M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
